Cisplatin (Platinol ®)
Genetic variability of HIF1A and response to treatment with cisplatin in combination with pemetrexed or gemcitabine in patients with malignant mesothelioma
Radiology and Oncology 2025 September 5 [Link] Matic Setina, Eva Setina, Ziga Doljak, Katja Goricar, Vita Dolzan, Viljem Kovac Abstract Background: Treatment of malignant mesothelioma (MM) still relies on chemotherapy with cisplatin in combination with pemetrexed or other drugs. Studies indicate that hypoxic conditions within tumour tissue may reduce responsiveness to cisplatin-based chemotherapy. Hypoxia-inducible factors…
Read MoreMiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial
Translational Oncology 2025 November [Link] Guénaëlle Levallet, Christian Creveuil, Alexandre Léger-Vigot, Solenn Brosseau, Claire Danel, Arnaud Scherpereel, Sylvie Lantuejoul, Julien Mazières, Laurent Greillier, Clarisse Audigier-Valette, Emmanuel Bergot, Denis Moro-Sibilot, Olivier Molinier, Hervé Léna, Isabelle Monnet, Franck Morin, Valérie Gounant, Gérard Zalcman Abstract We investigated whether angiogenesis-related microRNAs (miRNAs) predict survival in patients with pleural mesothelioma…
Read MoreInhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma
British Journal of Cancer 2025 September 4 [Link] Karin Schelch, Nadine Maach, Muhammad Hashim, Benjamin Zitta, Dominik Kirchhofer, Gerald Timelthaler, Anna Solta, Dominik Emminger, Verena Kopatz, Mir A Hoda, Walter Berger, Clemens Aigner, Balazs Dome, Glen Reid, Michael Grusch Abstract Background: The cold-shock domain protein YB-1 is overexpressed in pleural mesothelioma (PM) and was shown…
Read MorePemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab
Lung Cancer 2025 September [Link] Sawana Ono, Hirokazu Taniguchi, Koji Kuroda, Teppei Hashimoto, Asuka Okada, Yasuhiro Goto, Hidenori Kitai, Yoichi Nakamura, Shinsuke Ogusu, Tetsunari Hase, Takayo Ota 10, Noriyuki Ebi, Makoto Furugen, Taishi Harada, Yoshiaki Kinoshita, Takaki Mizoguchi, Katsumi Nakatomi, Yoshifumi Soejima, Takahiro Yamada, Shinnosuke Takemoto, Hiroshi Mukae Abstract There is limited evidence regarding the…
Read MoreInhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma
Oncogenesis 2025 August 11 [Link] Yantang Lin, Christelle Dubey, Tereza Losmanova, Samuel Oevgü Yasmin, Jean-Louis Reymond, Ren-Wang Peng, Haibin Deng, Patrick Dorn, Thomas Michael Marti Abstract Pleural mesothelioma (PM) is an aggressive, asbestos-linked cancer with limited treatment options and a poor prognosis. Lactate dehydrogenase B (LDHB) converts lactate to pyruvate, and its silencing reduces mitochondrial…
Read MoreInhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma
Oncogenesis 2025 August 11 [Link] Yantang Lin, Christelle Dubey, Tereza Losmanova, Samuel Oevgü Yasmin, Jean-Louis Reymond, Ren-Wang Peng, Haibin Deng, Patrick Dorn, Thomas Michael Marti Abstract Pleural mesothelioma (PM) is an aggressive, asbestos-linked cancer with limited treatment options and a poor prognosis. Lactate dehydrogenase B (LDHB) converts lactate to pyruvate, and its silencing reduces mitochondrial…
Read MoreA giant peritoneal mesothelioma extending to the pelvic floor: A case report and review of the literature
Journal of Cancer Research and Therapeutics 2025 April 1 [Link] Mathew Thomas, Harikrishnan Nandakumar, Parth Sampat, Stephen Graziano Abstract Malignant peritoneal mesothelioma (MPM) is a rare malignancy originating from the peritoneal serosa and is the second most common site of mesothelioma after the pleura. Localized disease presents as a focal circumscribed mass, whereas diffuse disease…
Read MoreDual Immunotherapy for Pericardial Mesothelioma That Developed After a Decade-Long Idiopathic Pericarditis: A Case Report
Respirology Case Reports 2024 May 26 [Link] Beatriz Grau Mirete, Paula Rodriguez Paya, Mariano Martinez Marin, Asia Ferrández Arias, Miguel Borregón Rivilla, Antonio David Lazaro Sanchez, Pedro Morillas Blasco, Alvaro Rodriguez-Lescure, Javier David Benítez Fuentes Abstract Malignant pericardial mesothelioma (MPeM) is exceptionally rare, and its association with long-standing idiopathic pericarditis remains unreported. We present a…
Read MoreEfficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma
Lung Cancer 2025 May [Link] Ernest Nadal, Paloma Martín-Martorell, Jose Carlos Benítez, Maria Ángeles Sala, Susana Cedrés, Carlos Álvarez, Manuel Dómine, Elia Sais 8, Maria Saigí, Rafael López, Laia Vilà, Bartomeu Massutí, Rosario García-Campelo, Andres Mesas-Ruiz, Amelia Insa, Sílvia Plans-Marín, Sara Hijazo-Pechero, Cristina Muñoz-Pinedo, Jesús Brenes, Mariano Provencio Abstract Objectives: We aimed to evaluate the…
Read MorePD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy
Non-Coding RNA Research 2025 February 21 [Link] Andrei Gurau, Suguru Yamauchi, Kaitlyn Ecoff, Kristen P Rodgers, James R Eshleman, Charles Conover Talbot Jr, Peng Huang, Joshua Choi, Patrick M Forde, Valsamo Anagnostou, Malcolm Brock, Yuping Mei Abstract Background: A new therapeutic avenue combining Durvalumab with cisplatin-pemetrexed (Durva-CP) has delivered a promising outcome for previously untreated…
Read More